Sarepta Therapeutics | SRPT - Gross Profit On Sales

Stock Price
17.38
Daily Change
-1.59 -8.38%
Monthly
-21.61%
Yearly
-83.14%
Q1 Forecast
18.29

Sarepta Therapeutics reported $43.55M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amgen USD 6.48B 307M Sep/2025
BioCryst Pharmaceuticals USD -88.88M 202.74M Dec/2024
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Capricor Therapeutics 0 11.13M Mar/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Gilead Sciences USD 6.31B 106M Dec/2025
Incyte USD 1.39B 118.68M Dec/2025
Insmed USD 217.69M 106.25M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Moderna USD 226M 583M Dec/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Novavax USD 23.89M 239.21M Sep/2024
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Tectonic Therapeutic USD 0 0 Mar/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025